FDA approves Orca Bio Tregzi first regulatory T-cell therapy for chronic graft-versus-host disease
Blood-cancer patients who get a donor stem-cell transplant risk chronic graft-versus-host disease, a feared complication where the graft attacks the recipient's own tissue. The FDA has now approved Tregzi, made by Orca Bio, the first regulatory T-cell therapy designed to reduce i
Patients who receive a donor stem-cell transplant to treat blood cancer face a specific, feared danger: chronic graft-versus-host disease, a condition in which the transplanted immune cells recognize the recipient's own body as foreign and attack it. It is one of the most serious long-term complications of allogeneic stem-cell transplantation, and options to prevent it have been limited. The US FDA has now approved Tregzi, developed by Orca Bio, described as the first regulatory T-cell therapy cleared to reduce chronic graft-versus-host disease. Regulatory T cells, often called Tregs, act as the immune system's natural brakes, holding other immune cells in check. Turning them into a therapy aims to calm the over-reactive donor response without simply shutting down the immune system wholesale. What makes this notable is that it is a new category of treatment rather than another variation on existing immunosuppressant drugs. For transplant physicians, it offers a fresh tool against a complication that has long shadowed an otherwise life-saving procedure. As with any newly approved cell therapy, real-world use over the coming months will show how its benefits hold up outside the trial setting.